DSM bolsters lactase portfolio

DSM-bolsters-lactase-portfolio.jpg
Maxilact Super is a ‘one-stop-shop’ enzyme innovation suitable for all lactose-free dairy applications. Pic: DSM

Royal DSM, a global science-based company active in nutrition, health and sustainable living, has launched its new Maxilact Super lactase enzyme.

Advancing DSM’s portfolio of Maxilact lactases, Maxilact Super enables dairy manufacturers to create high-quality, clean-tasting lactose-free and sugar-reduced dairy, while also helping cut hydrolysis time by 33% and achieve optimal production efficiency.

Maxilact Super is suitable for all dairy product positionings, from regular to organic and Verband Lebensmittel Ohne Gentechnik (VLOG). With this new enzyme, DSM said lactose-free dairy producers can deliver the authenticity, health appeal and sensory experience consumers expect in all applications, without adding complexity to the production process.

The popularity of the lactose-free dairy category continues: DSM said its research showed 71% of consumers are expecting to reduce their sugar intake in the next three to five years.

For lactose-free dairy producers, developing products that align with consumer preferences creates opportunities to differentiate their portfolio, DSM said, while elevating the need for efficient production and increased capacity to stay competitive.

Maxilact Super, the company said, is a ‘one-stop-shop’ enzyme innovation suitable for all lactose-free dairy applications, whether it is milk, milk drinks or yogurt, enabling manufacturers to ‘live’ their labels and create authentic, appealing dairy.

It also offers sugar-reduced options by unlocking the natural sweetness of dairy by breaking down lactose into its sweeter forms, effectively lowering the sugar levels in products by up to as much as 20%. Plus, the Maxilact Super technology helps achieve higher enzyme activity, meaning producers can cut hydrolysis time by a third and achieve a double-digit increase in production efficiency, while also boosting capacity without capex investment.

As part of DSM’s range of Maxilact lactase solutions – including Maxilact Smart and Maxilact LGi – Maxilact Super is free from invertase and arylsulfatase, which can produce off-flavors and reduce stability during the shelf life of dairy products.

“With 71% of consumers checking the labels of the products they purchase, combined with the ever-growing preference for lactose-free dairy and the sugar reduction trend that is here to stay, it is clear that prioritizing health and authenticity is more important than ever for individuals today,” Ben Rutten, global business manager for milk at DSM, said.

“DSM understands the challenges these diverse needs create for lactose-free dairy manufacturers, and with the innovative Maxilact Super solution, producers across the globe can efficiently deliver high-quality sugar-reduced and lactose-free dairy with next generation consumer appeal.”